Ajani, Jaffer A.
Javle, Milind
Eng, Cathy
Fogelman, David
Smith, Jackie
Anderson, Barry
Zhang, Chun
Iizuka, Kenzo
Funding for this research was provided by:
Delta-Fly Pharma., Inc (N/A)
Article History
Received: 31 July 2019
Accepted: 15 April 2020
First Online: 6 May 2020
Compliance with ethical standards
:
: Jaffer Ajani declares receiving grants/research support from Delta-Fly Pharma, Inc., ProLynx, Bristol-Myers Squibb, Merck, Astellas, Roche, Zymeworks, Eli Lilly, Taiho Pharmaceutical, and honoraria or consultation fees from Bristol-Myers Squibb, Merck, Astellas, Eli Lilly, AstraZeneca, Daiichi Sankyo, Roche. Milind Javle declares receiving honoraria or consultation fees from Rafael Pharmaceuticals, Incyte, Pieris Pharmaceuticals, Merck, Novartis, Seattle Genetics, BeiGene, QED Therapeutics, Bayer. Cathy Eng declares that she has no conflict of interest. David Fogelman declares receiving grants / research support from Delta-Fly Pharma, Inc. Jackie Smith declares that she has no conflict of interest. Barry Anderson declares that he has no conflict of interest. Chun Zhang is an employee of Delta-Fly Pharma, Inc. Kenzo Iizuka is an executive officer of Delta-Fly Pharma, Inc.
: This study was conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH/GCP), the protocol, all applicable regulatory requirements, and guiding principles of the Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the study.